Development of a High Throughput System for Testing of Adjuvants for Toxicity and Efficacy

This project aims to create an integrated, scalable platform to accelerate and standardize preclinical evaluation of vaccine adjuvants. Recognizing that adjuvant selection is critical to vaccine performance yet often constrained by slow, resource-intensive testing paradigms, this initiative seeks to design and validate a high-throughput workflow that combines automated in vitro assays, multiplexed readouts and streamlined data analysis to assess both safety (toxicity) and functional immune-enhancing properties (efficacy) of candidate adjuvants. The system will enable parallel screening of large adjuvant libraries across diverse biological contexts, allowing researchers to rapidly identify promising formulations while eliminating those with adverse safety profiles early in development. Core components include standardized cell-based assays representing key immune cell types, cytokine and biomarker multiplex assays to capture broad immune activation signatures, cytotoxicity and viability measures to detect deleterious effects, and computational pipelines to integrate multi-parameter datasets into actionable rank-ordering of adjuvant candidates.

The platform emphasizes reproducibility and translatability. By employing well-characterized cell models and harmonized assay conditions, the system reduces variability between runs and laboratories. Multiplexed readouts, including secreted cytokines, surface marker expression, and cell viability metrics, provide a rich phenotype for each adjuvant, enabling nuanced assessment beyond single endpoints. Advanced data analytics and visualization tools will support dose-response modeling, potency estimation, and safety thresholds, guiding rational down-selection. The design also contemplates tiered testing: high-throughput in vitro screening to prioritize candidates, followed by more detailed mechanistic assays and targeted in vivo validation for the top-ranked adjuvants.

Beyond screening efficiency, the project prioritizes safety by integrating toxicity-focused assays early and systematically. Detecting cytotoxicity, excessive inflammatory responses, or undesirable activation patterns at the screening stage reduces downstream attrition and ethical burdens associated with late-stage failures. The platform's ability to evaluate efficacy-related readouts-such as induction of key cytokines, antigen-presenting cell maturation markers, and signatures predictive of adaptive immune responses, supports selection of adjuvants likely to produce robust and appropriate immune outcomes.

Implementation will involve cross-disciplinary collaboration among immunologists, assay development specialists, bioengineers, and data scientists to ensure the system's technical robustness and biological relevance. Validation efforts will benchmark the platform against known adjuvants with established clinical or preclinical profiles to demonstrate predictive value. Ultimately, this high-throughput testing system aims to accelerate vaccine adjuvant discovery, improve candidate selection quality, reduce resource use and time-to-decision, and contribute to safer, more effective vaccine formulations.